Amy Early

MD
Medical Oncology
2022 Buffalo Spree Top Docs badge

Dr. Early is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2022

Specializing In:

Breast cancer

About Amy Early

Positions

Roswell Park Comprehensive Cancer Center

  • Associate Professor of Oncology
  • Department of Medical Oncology

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Clinical Professor of Medicine

Background

Education and Training:

  • 1976 - MD - Drexal University College of Medicine (Hahnemann), Philadelphia, PA

Residency:

  • 1976-1978 - Internal Medicine - University at Buffalo Consortium, Buffalo, NY

Fellowship:

  • 1998 - Master Clinical Teaching Fellowship - University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY
  • 1978-1980 - Medical Oncology - Roswell Park Comprehensive Cancer Center, Buffalo, NY

Board Certification:

  • 1981 - Certification in Medical Oncology
  • 1979 - American Board of Internal Medicine, Certification in Internal Medicine

Professional Memberships:

  • American Society of Clinical Oncology
  • Medical Society of the County of Erie & State of New York
  • Heart, Lung & Cancer Committee, Medical Society of the State of New York

Professional Experience:

  • 2014-Present - Roswell Park Comprehensive Cancer Center, Buffalo, NY
  • 1983-2014 - Buffalo Medical Group, PC, Buffalo, NY
  • 1980-1983 - Roswell Park Cancer Institute, Buffalo, NY

Honors & Awards:

  • 1985 - Fellow, American College of Physicians
4 Things You Might Not Know About Cancer Staging

Featured on Cancer Talk

4 Things You Might Not Know About Cancer Staging

Publications

Early AP and Moon W. Breast Cancer and Secondary Cancer Recurrences After Autologous Tissue Reconstruction. Clin Breast Cancer Available online August 3, 2020. https://doi.org/10.1016/j.clbc.2020.07.015

Early A, Pabla S, Conroy JM, Nesline MK, Glenn S, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, DePietro P, Lenzo F,Wang Y, Morrison C. Immune Subsets by GI Tumor Type. Society for Immunotherapy of Cancer 33rd Annual Meeting. November 9, 2018 (poster).

Pabla S, Conroy J, Nesline M, Glenn ST, Pananicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Wany Y, Gy G, Yau H, Early A, Chen H, Bshara W, Madden KG, Shiirai K, Dragnev KH, Tage LJ, Marin D, Ahy J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernanzez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacobs R, Dressler L, Steciuk M, Binns O, Kusuganti DR, Shal N, Ernstoff M, Osunsi K, Kurrock R, Gardner M, Galluzzi L, Morrison C.
Proliferative Potential and Resistance to Immune Checkpoint Blockade in Lung Cancer Journal for ImmunoTherapy of Cancer. Journal for ImmunoTherapy of Cancer Feb 1;7(1):27, 2019. doi: 10.1186/s40425-019-503-3 PMID 30709424 PMID:30709424

Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing. BMC Med Inform Decis Mak. 2019 Jan 18;19(1):14. doi: 10.1186/s12911-019-0743-x. PMID: 30658646

Pruthi S, Simon J, Early AP. A Current Overview of the Management of Urogenital Atrophy in Women with Breast Cancer. The Breast Journal 17(4):403-408, 2011. PMID: 21645165